Who We Are
Tianhe Stem Cell Biotechnologies Inc., is an American company that manufactures multipotent stem cells from human cord blood and adult blood, with the goal of developing clinical applications to treat or cure diabetes (both type 1 and type 2) and other autoimmune diseases. Tianhe also has a major division in China (Jinan Tianhe Stem Cell Biotechnology Co., Ltd.) dedicated to supporting the mission of the overall company. Tianhe has a global exclusive license agreement for all Stem Cell Educator technologies from the University of Illinois at Chicago where Dr. Yong Zhao, Founder and President of Tianhe, originally conceived of Stem Cell Educator therapy, developed a prototype device, and demonstrated its safety and clinical efficacy in multi-center clinical studies.
Stem Cell Educator Therapy is a non-invasive treatment of autoimmune related diseases developed by Dr. Yong Zhao using stem cells drawn from human umbilical-cord blood. Educator Therapy has the potential to treat diseases including psoriasis, alopecia areata, grave's disease, and diabetes; Tianhe have focused its primary research and application in developing a cure for diabetes. Our clinical data provide powerful evidence that Educator Therapy can balance the immune system and restore metabolic control in long-standing diabetic patients.
More than 200 type 1 and type 2 diabetes patients between the ages of 3 and 60 have been treated with the Stem Cell Educator Therapy. Patients varying in gender, age, severity, and race produced suggestive evidence to indicate the safety and efficacy of the procedure. Five partner locations around the world are continuing to run trials with follow ups to fine-tune the procedure for clinical application.
Of Dr. Zhao's 40 peer reviewed journal publications, 17 of them are featured here documenting the discovery, research, and clinical study of the Stem Cell Educator. Publications include BMC Medicine, Diabetes, Stem Cells Translational Medicine, EBioMedicine, Autoimmunity Reviews, and Chinese Journal of Diabetes.
Insulin is not a cure
Most conventional immune therapies for type 1 diabetes has failed over the past 30 years. Clinical trials reveal that a single treatment with the Stem Cell Educator provides a lasting reversal of autoimmunity that allows regeneration of islet beta cells and improvement of metabolic control in long-standing subjects.
There is no safe insulin sensitizer to overcome insulin resistance of type 2 diabetes. Research shows that Stem Cell Educator Therapy is an innovative, safe and effective approach that produce lasting improvements in metabolic control of moderate and severe subjects.
Increasing diabetes market
The rapidly increasing diabetes epidemic projects a 64% total increase in the US by 2025. Annual Medicare cost will increase by 72%, with $541 billion per year (75th ADA report).
Expansion of technology
Clinical studies have demonstrated the therapeutic efficacy of Stem Cell Educator Therapy in the treatment of other autoimmune diseases such as Alopecia Areata and Psoriasis.
14 years of research, 16 journal publications, and medical experts on 4 continents have evidenced the molecular and cellular mechanisms underlying the efficacy of Stem Cell Educator Therapy.
Top 3 in the world
Stem Cell Educator Therapy is ranked as one of the top 3 practical cures in the world to hold the most promising cure for type 1 diabetes. (Juvenile Diabetes Cure Alliance: State of the Cure 2013).
Yong Zhao MD, PhD
Founder & Owner
In 2005, Dr. Zhao discovered cord blood-derived multipotent stem cells (CB-SC) and successfully translated it into clinical use. Dr. Zhao also invented Stem Cell Educator Therapy for the treatment of type 1 and type 2 diabetes and other autoimmune diseases in humans. This groundbreaking study has been noted by the American Diabetes Association at the 72nd Scientific Sessions (ADA, Philadelphia, 2012) as one of eight major diabetes breakthroughs in 2012. His work received the 2006 and 2008 Rachmiel Levine Scientific Achievement Award and was covered by CNN, USA Today, Reuters, and Science Daily. He has 40 peer-reviewed publications and owns 8 patents including 3 international PCT patents and 5 national patents in United States.